Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
DXO2MR
|
||||
| Drug Name |
1-[3-(4-Methyl-piperazin-1-yl)-propyl]-4-(3-thiophen-3-yl-pyrazolo[1,5-a]pyrimidin-6-yl)-1H-pyridin-2-one
|
||||
| Synonyms |
CHEMBL118400
|
||||
| Indication | Discovery agent | Investigative | [1587926] | ||
| Formula |
C23H26N6OS
|
||||
| Canonical SMILES |
CN1CCN(CCCN2C=CC(=CC2=O)c3cnc4c(cnn4c3)c5ccsc5)CC1
|
||||
| InChI |
InChI=1S/C23H26N6OS/c1-26-8-10-27(11-9-26)5-2-6-28-7-3-18(13-22(28)30)20-14-24-23-21(15-25-29(23)16-20)19-4-12-31-17-19/h3-4,7,12-17H,2,5-6,8-11H2,1H3
|
||||
| InChIKey |
QZNBJKPMALDRGE-UHFFFAOYSA-N
|
||||
| Target and Pathway | |||||
| Target(s) | Vascular endothelial growth factor receptor 2 | Target Info | [1587926] | ||
| Vascular endothelial growth factor receptor 1 | Target Info | [1587926] | |||
| KEGG Pathway | Ras signaling pathway | ||||
| Rap1 signaling pathway | |||||
| Cytokine-cytokine receptor interaction | |||||
| Endocytosis | |||||
| PI3K-Akt signaling pathway | |||||
| VEGF signaling pathway | |||||
| Focal adhesion | |||||
| Proteoglycans in cancerhsa04014:Ras signaling pathway | |||||
| HIF-1 signaling pathway | |||||
| Transcriptional misregulation in cancer | |||||
| Rheumatoid arthritis | |||||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| PANTHER Pathway | Angiogenesis | ||||
| VEGF signaling pathway | |||||
| Pathway Interaction Database | HIF-2-alpha transcription factor network | ||||
| Beta3 integrin cell surface interactions | |||||
| Signaling events mediated by TCPTP | |||||
| SHP2 signaling | |||||
| S1P1 pathway | |||||
| VEGF and VEGFR signaling network | |||||
| Integrins in angiogenesis | |||||
| Signaling events mediated by VEGFR1 and VEGFR2 | |||||
| Notch-mediated HES/HEY networkglypican_1pathway:Glypican 1 network | |||||
| S1P3 pathway | |||||
| VEGFR1 specific signals | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.